GGrantIndex
← Search

Emory Winship Cancer Institute Cancer Center Support Grant

$115,904P30FY2009CANIH

Emory University, Atlanta GA

Investigators

Linked publications, trials & patents

Trial NCT07405476Trial NCT07213154Trial NCT07174570Trial NCT07155317Trial NCT07150546Trial NCT07140679Trial NCT07112690Trial NCT07104240Trial NCT07101445Trial NCT06914999Trial NCT06868433Trial NCT06865768Trial NCT06799481Trial NCT06760507Trial NCT06731270Trial NCT06709534Trial NCT06708351Trial NCT06674863Trial NCT06662058Trial NCT06650579Trial NCT06636734Trial NCT06595160Trial NCT06583148Trial NCT06541158Trial NCT06534125Trial NCT06495125Trial NCT06492759Trial NCT06492070Trial NCT06423326Trial NCT06328699Trial NCT06328686Trial NCT06324240Trial NCT06254911Trial NCT06132685Trial NCT06105918Trial NCT06008730Trial NCT06006013Trial NCT05998135Trial NCT05877859Trial NCT05873608Trial NCT05798507Trial NCT05779943Trial NCT05756569Trial NCT05733351Trial NCT05526872Trial NCT05514912Trial NCT05513859Trial NCT05506982Trial NCT05493566Trial NCT05488145Trial NCT05464810Trial NCT05391750Trial NCT05387915Trial NCT05368428Trial NCT05346692Trial NCT05341349Trial NCT05320406Trial NCT05315687Trial NCT05310448Trial NCT05274763Trial NCT05250895Trial NCT05245682Trial NCT05244239Trial NCT05208307Trial NCT05204160Trial NCT05103904Trial NCT05091866Trial NCT05086731Trial NCT05039073Trial NCT05017610Trial NCT04908709Trial NCT04895592Trial NCT04890236Trial NCT04883437Trial NCT04878029Trial NCT04848519Trial NCT04776395Trial NCT04762199Trial NCT04754945Trial NCT04750473Trial NCT04731376Trial NCT04725903Trial NCT04676087Trial NCT04590664Trial NCT04585724Trial NCT04524702Trial NCT04483206Trial NCT04433949Trial NCT04428671Trial NCT04393350Trial NCT04366791Trial NCT04361552Trial NCT04352205Trial NCT04348292Trial NCT04340882Trial NCT04278118Trial NCT04276194Trial NCT04262869Trial NCT04191421Trial NCT04144127

Abstract

DESCRIPTION (provided by applicant): The Winship Cancer Institute (WCI) at Emory University is a multidisciplinary matrix center that supports, facilitates, coordinates, and centralizes cancer research, quality oncology care, education, and dissemination at Emory University and its affiliate institutions in order to reduce the burden of cancer, associated morbidity, and mortality in the state of Georgia, the Southeastern region, and the U.S. Its Director, Brian Leyland-Jones, MD, PhD, also serves as Associate Vice-President in the Woodruff Health Sciences Center and leads an expert team of Senior Leadership, Program Leaders, and Core Directors. The 152 WCI members engage in four scientific programs: Cancer Genetics and Epigenetics (CGE), Molecular Pathways and Biomarkers (MPB), Discovery and Drug Development (DDT), and Cancer Control and Population Sciences (CCPS). Shared core resources provide services in Clinical Trials, Cell Imaging and Microscopy, Biomarker Profiling, Biostatistics, and Human Tissue and Pathology. The WCI currently occupies dedicated facilities of over 350,000 nsf under the direct control of the Director. During the P20 Planning Grant period, the WCI's NCI funding grew from $9.49 million to its current mark of $25 million in NCI grants out of a total of $55.4 million in extramural, peer-reviewed cancer funding. This growth has been facilitated by the extensive recruiting of new faculty to Emory, resulting in 88 new recruits from 19 different departments across the Schools of Medicine, Public Health, Nursing, and Emory College. Other noteworthy accomplishments during this planning period have been substantial progress in clinical trials as measured by total accruals and accruals to investigator-initiated studies, and the success in team science awards, including multiple P01's, P20's, P60, the U54 Cancer Center for Nanotechnology Excellence, and a Head and Neck SPORE. The WCI has received extensive institutional support, including more than $95 million in University funding to support infrastructure and new initiatives, plus $103 million for the construction of the WCI building dedicated in 2002. Beyond funding, Emory has been committed to elevating the status of the cancer center within the University;enhancing the organizational position of the cancer center within the Woodruff Health Sciences Center;and ensuring the sustained authority of the Director. The WCI also benefits from intense support from its community partners, including the Georgia Cancer Coalition (GCC), which has provided over $28 million in support to 51 GCC Scholars among WCI members;the American Cancer Society;the CDC;and other area-based institutions, including the Georgia Institute of Technology and Morehouse School of Medicine. Developmental funds are requested for a Transgenic Mouse and Gene Targeting Core and essential Bioinformatics technology. The WCI is well-positioned to continue to advance its progress as it pursues NCI-designation as a cancer center, and to fulfill its mission to reduce the burden of cancer throughout the state of Georgia.

View original record on NIH RePORTER →